Cutler Group LP Aurinia Pharmaceuticals Inc. Put Options Transaction History

Cutler Group LP

17 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Jan 18, 2024	BUY	$7.13 - $9.49 $29,946 - $39,858	4,200 New	4,200 $6,000
Q2 2023 Jul 18, 2023	BUY	$8.96 - $11.69 $6,272 - $8,183	700 Added 350.0%	900 $0
Q1 2023 May 01, 2023	BUY	$5.94 - $11.27 $1,188 - $2,254	200 New	200 $0
Q3 2022 Oct 25, 2022	BUY	$6.66 - $12.39 $1,998 - $3,717	300 New	300 $0
Q1 2022 Apr 14, 2022	SELL	$10.05 - $22.48 $400,995 - $896,952	-39,900 Reduced 82.61%	8,400 $23,000
Q4 2021 Jan 18, 2022	BUY	$17.78 - $33.08 $380,492 - $707,912	21,400 Added 79.55%	48,300 $42,000
Q3 2021 Oct 26, 2021	BUY	$10.93 - $23.55 $135,532 - $292,020	12,400 Added 85.52%	26,900 $13,000
Q2 2021 Jul 19, 2021	BUY	$10.0 - $14.52 $121,000 - $175,692	12,100 Added 504.17%	14,500 $16,000
Q1 2021 Apr 26, 2021	BUY	$12.3 - $18.73 $4,920 - $7,492	400 Added 20.0%	2,400 $10,000
Q3 2020 Oct 27, 2020	SELL	$13.19 - $16.66 $39,570 - $49,980	-3,000 Reduced 60.0%	2,000 $12,000
Q2 2020 Jul 22, 2020	BUY	$14.12 - $18.33 $24,004 - $31,160	1,700 Added 51.52%	5,000 $18,000
Q1 2020 May 07, 2020	BUY	$11.34 - $21.46 $3,402 - $6,438	300 Added 10.0%	3,300 $17,000
Q4 2019 Feb 06, 2020	SELL	$3.88 - $21.42 $13,580 - $74,970	-3,500 Reduced 53.85%	3,000 $10,000
Q3 2019 Oct 28, 2019	BUY	$5.34 - $6.59 $8,010 - $9,885	1,500 Added 30.0%	6,500 $22,000
Q2 2018 Aug 10, 2018	BUY	$5.06 - $6.36 $13,661 - $17,172	2,700 Added 117.39%	5,000 $2,000
Q4 2017 Jan 17, 2018	SELL	$4.53 - $7.09 $104,190 - $163,070	-23,000 Reduced 90.91%	2,300 $1,000
Q3 2017 Oct 17, 2017	BUY	$5.71 - $6.9 $144,463 - $174,570	25,300	25,300 $60,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.